Verastem reports 83% ORR in RAMP 205 PDAC trial; details VS-7375 KRAS G12D inhibitor

Verastem, Inc.

FDA approved avutometinib + defactinib (AVMAPKI/FAKZYNJA) on May 8, 2025 for KRAS-mutated recurrent LGSOC.
RAMP 205 Phase 1/2 in first-line mPDAC: 83% unconfirmed ORR (10/12) at dose level 1; all patients had tumor shrinkage.
RP2D set: avutometinib 2.4mg, defactinib 200mg, gemcitabine 800mg/m2, nab-paclitaxel 125mg/m2.
VS-7375: oral KRAS G12D ON/OFF inhibitor with potent preclinical selectivity and activity; Phase 1/2a trial planned.
Preliminary data suggest patients may exceed historical median PFS for gemcitabine/nab-paclitaxel.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.